Literature DB >> 23233384

Leukoaraiosis and sex predict the hyperacute ischemic core volume.

Nils Henninger1, Eugene Lin, Diogo C Haussen, Laura L Lehman, Deepak Takhtani, Magdy Selim, Majaz Moonis.   

Abstract

BACKGROUND AND
PURPOSE: Leukoaraiosis (LA) and male sex have been associated with decreased cerebrovascular reactivity, which potentially adversely affects tissue viability in acute stroke. Therefore, we aimed to elucidate the contribution of LA-severity and sex to the extent of the hyperacute ischemic core volume after intracranial large artery occlusion.
METHODS: We analyzed data from 87 patients with acute intracranial large artery occlusion who had acute multimodal computed tomography-imaging. LA-severity was assessed using the van Swieten scale on noncontrast computed tomography. Computed tomography perfusion data were analyzed using automatic calculation of the mean transit time and hyperacute cerebral blood volume defects. Multivariate linear and logistic regression analyses were used to identify independent predictors of the hyperacute infarct-volume.
RESULTS: Severe LA (van Swieten Scale, 3-4; odds ratio, 43.22; 95% CI, 6.26-298.42; P<0.001) and male sex (odds ratio, 7.52; 95% CI, 1.38-40.86; P=0.020) were independently associated with a hyperacute cerebral blood volume-lesion >25 mL on multivariate logistic regression analysis. Multivariate linear regression analysis confirmed the association between severe LA (P<0.001) and male sex (P=0.01) with larger cerebral blood volume-lesions. There was no significant difference in the absolute or relative mean transit time-lesion volumes when stratified by LA-severity or sex. Women had significantly smaller cerebral blood volume-lesion volumes compared with men (P=0.036).
CONCLUSIONS: Severe LA and male sex are associated with larger infarct cores, which adds to the notion that sex and LA alter the brain's intrinsic susceptibility to acute cerebral ischemia. Future, larger studies are needed to confirm our observation that women have smaller core volumes and its significance.

Entities:  

Mesh:

Year:  2012        PMID: 23233384      PMCID: PMC3543730          DOI: 10.1161/STROKEAHA.112.679084

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  26 in total

1.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

Review 2.  Imaging-based selection in acute ischemic stroke trials - a quest for imaging sweet spots.

Authors:  Andrew M Demchuk; Bijoy Menon; Mayank Goyal
Journal:  Ann N Y Acad Sci       Date:  2012-09       Impact factor: 5.691

3.  Gender-linked brain injury in experimental stroke.

Authors:  N J Alkayed; I Harukuni; A S Kimes; E D London; R J Traystman; P D Hurn
Journal:  Stroke       Date:  1998-01       Impact factor: 7.914

4.  Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials.

Authors:  David M Kent; Lori Lyn Price; Peter Ringleb; Michael D Hill; Harry P Selker
Journal:  Stroke       Date:  2004-11-29       Impact factor: 7.914

5.  Patterns of cerebral blood flow reduction in patients with ischemic leukoaraiosis.

Authors:  M O'Sullivan; D J Lythgoe; A C Pereira; P E Summers; J M Jarosz; S C R Williams; H S Markus
Journal:  Neurology       Date:  2002-08-13       Impact factor: 9.910

6.  Severity of leukoaraiosis and susceptibility to infarct growth in acute stroke.

Authors:  Hakan Ay; E Murat Arsava; Jonathan Rosand; Karen L Furie; Aneesh B Singhal; Pamela W Schaefer; Ona Wu; R Gilberto Gonzalez; Walter J Koroshetz; A Gregory Sorensen
Journal:  Stroke       Date:  2008-03-13       Impact factor: 7.914

7.  Grading white matter lesions on CT and MRI: a simple scale.

Authors:  J C van Swieten; A Hijdra; P J Koudstaal; J van Gijn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-12       Impact factor: 10.154

8.  Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke.

Authors:  Max Wintermark; Adam E Flanders; Birgitta Velthuis; Reto Meuli; Maarten van Leeuwen; Dorit Goldsher; Carissa Pineda; Joaquin Serena; Irene van der Schaaf; Annet Waaijer; James Anderson; Gary Nesbit; Igal Gabriely; Victoria Medina; Ana Quiles; Scott Pohlman; Marcel Quist; Pierre Schnyder; Julien Bogousslavsky; William P Dillon; Salvador Pedraza
Journal:  Stroke       Date:  2006-03-02       Impact factor: 7.914

9.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

10.  The anterior cerebral artery is an appropriate arterial input function for perfusion-CT processing in patients with acute stroke.

Authors:  Max Wintermark; Benison C Lau; Jeffrey Chien; Sandeep Arora
Journal:  Neuroradiology       Date:  2007-12-05       Impact factor: 2.804

View more
  23 in total

1.  White Matter Hyperintensity-Adjusted Critical Infarct Thresholds to Predict a Favorable 90-Day Outcome.

Authors:  Jatinder Patti; Johanna Helenius; Ajit S Puri; Nils Henninger
Journal:  Stroke       Date:  2016-09-15       Impact factor: 7.914

2.  Severe leukoaraiosis portends a poor outcome after traumatic brain injury.

Authors:  Nils Henninger; Saef Izzy; Raphael Carandang; Wiley Hall; Susanne Muehlschlegel
Journal:  Neurocrit Care       Date:  2014-12       Impact factor: 3.210

3.  White matter burden does not influence the outcome of mechanical thrombectomy.

Authors:  Laura Mechtouff; Norbert Nighoghossian; Camille Amaz; Marielle Buisson; Yves Berthezène; Laurent Derex; Elodie Ong; Omer Faruk Eker; Tae-Hee Cho
Journal:  J Neurol       Date:  2019-11-08       Impact factor: 4.849

Review 4.  Association between Leukoaraiosis and Poor Outcome is not due to Reperfusion Inefficiency after Intravenous Thrombolysis.

Authors:  Genlong Zhong; Shenqiang Yan; Sheng Zhang; Qingmeng Chen; Yangxiao Lai; Min Lou
Journal:  Transl Stroke Res       Date:  2016-06-02       Impact factor: 6.829

Review 5.  Recent Advances in Leukoaraiosis: White Matter Structural Integrity and Functional Outcomes after Acute Ischemic Stroke.

Authors:  Mark R Etherton; Ona Wu; Natalia S Rost
Journal:  Curr Cardiol Rep       Date:  2016-12       Impact factor: 2.931

6.  Biomarkers of stroke recovery: Consensus-based core recommendations from the Stroke Recovery and Rehabilitation Roundtable.

Authors:  Lara A Boyd; Kathryn S Hayward; Nick S Ward; Cathy M Stinear; Charlotte Rosso; Rebecca J Fisher; Alexandre R Carter; Alex P Leff; David A Copland; Leeanne M Carey; Leonardo G Cohen; D Michele Basso; Jane M Maguire; Steven C Cramer
Journal:  Int J Stroke       Date:  2017-07       Impact factor: 5.266

7.  White matter hyperintensity lesion burden is associated with the infarct volume and 90-day outcome in small subcortical infarcts.

Authors:  J Helenius; Y Mayasi; N Henninger
Journal:  Acta Neurol Scand       Date:  2016-08-29       Impact factor: 3.209

8.  Impact of leukoaraiosis on parenchymal hemorrhage in elderly patients treated with thrombolysis.

Authors:  Norbert Nighoghossian; Fatima Abbas; Tae-Hee Cho; Ana Filipa Geraldo; Vincent Cottaz; Elie Janecek; Laura Mechtouff; Magali Bischoff; Carlos El Khoury; Anne Marie Schott; Laurent Derex; Marc Hermier; Louis Guy Tisserand; Roxana Amelie; Leila Chamard; Yves Berthezene
Journal:  Neuroradiology       Date:  2016-07-22       Impact factor: 2.804

9.  Leukoaraiosis predicts a poor 90-day outcome after endovascular stroke therapy.

Authors:  J Zhang; A S Puri; M A Khan; R P Goddeau; N Henninger
Journal:  AJNR Am J Neuroradiol       Date:  2014-07-03       Impact factor: 3.825

10.  White matter disease as a biomarker for long-term cerebrovascular disease and dementia.

Authors:  Aurauma Chutinet; Natalia S Rost
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.